| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
SANTA CLARA, Calif.—In a move that expands its footprint in the areas of cardiovascular and metabolic disease, Crown Bioscience Inc., a wholly owned subsidiary of Crown Bioscience International, has announced that it will acquire Indianapolis-based PreClinOmics Inc., an in-vivo preclinical company specializing in early research in cardiovascular and metabolic diseases (CVMD) as well as renal disease and neurology.
 
Dr. Jean-Pierre Wery, president of Crown Bioscience, commented that, “The acquisition of PreClinOmics will allow CrownBio to create a center of excellence in global translational drug development specifically for cardiovascular and metabolic disease. We are confident that the acquisition will ultimately result in greater success in clinical trials and lower the cost of drug development for diseases that produce some of the highest economic costs in the world.”
 
PreClinOmics was incorporated in 2001, and is an AAALAC Accredited contract resource organization, with offerings such as Discovery Services, Analytical services, ADME/PK services, Safety/non-GLP Toxicology services and genetic models. Following the acquisition, PreClinOmics will retain its name, specifically as “PreClinOmics, a Crown Bioscience company.”
 
“PreClinOmics has an excellent track record, and scientific reputation in the CVMD research and pharmaceutical industry; thus this is an outstanding opportunity for CrownBio to expand our capabilities to serve the needs of this community,” Dr. Jim Wang, senior vice president of CVMD research at Crown Bioscience, added in a press release.
 
PreClinOmics brings with it some of the most highly translational models to effectively screen compounds for efficacy and reduce the complications of CVMD diseases. Unlike other commercially available models, the models in the PreClinOmics product line develop adult onset type 2 diabetes and all the diabetic complications without relying on mutations in the leptin signaling. PreClinOmics' rat models include the ZDSD rat and FATZO mouse for diabetes, both of which are obese and hyperglycemic, as well as pcy and jck mice for polycystic kidney disease, in partnership with the Polycystic Kidney Disease Foundation.
 
“We are thrilled to join Crown Bioscience. The drug development industry will now have a single source that offers the best models available in both cardiovascular and metabolic diseases,” Joseph Pesek, chief executive officer and co-founder of PreClinOmics, remarked in a statement on the transaction. “We are excited for the opportunities the acquisition has given us, especially with the reputation that CrownBio has earned with the experience and global resources it offers the market.”
 
 
SOURCE: Crown Bioscience press release

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue